FGEN (FibroGen, Inc.) Forward P/S Multiple

Corporate emblem and logo of FibroGen (FGEN)

Demand for medical developments remains stable, yet biotech success is tied to liquidity levels. The forward P/S of FibroGen, Inc. (FGEN) reflects the asset's value dynamics, where the current status is 4.70. Delisting risks and a capital shortage following the pamrevlumab collapse are weighing on the share price, while roxadustat sales in China and the partnership with AstraZeneca create growth potential.

FibroGen - FGEN Price-to-Projected Revenue Ratio (period 07/04/2022 - 01/08/2026)

FGEN (FibroGen Corporation): analytical breakdowns and indicator data

- current price and projected stock value:
Stock Price FibroGen|FGEN - Forecast Levels Chart
- business market valuation indicators:
Market Capitalization FibroGen Corporation|FGEN - Company Buyout Price
- issuer book value statistics:
Book Value per Share FibroGen|FGEN - Company Book Value|Market Value to Book Value Ratio fibrogen.com|FGEN - Aggregate Asset Value
- company liabilities and liquidity data:
Debt to Equity FibroGen, Inc.|FGEN - Long-Term Liabilities to Capital|Short-Term Debt to Capital FibroGen, Inc.|FGEN - Company Total Indebtedness|Debts to Book Capitalization FibroGen Corporation|FGEN - Long-Term Debt|Company Short-Term Debt FibroGen|Quick Liquidity Indicator fibrogen.com
- financial results and valuation multiples details:
FGEN - Final Profit|Projected Future Earnings FibroGen, Inc.|FGEN - Business Payback Period|Future Price to Earnings FibroGen Corp|FGEN - Growth-Adjusted P/E Ratio|EV/EBITDA Multiple FibroGen Corporation|FGEN - Operating profit before deduction of amortization|Net earnings per share for the last 12 months FibroGen|FGEN - Net earnings per share for the last four quarters|Quarterly EPS earnings growth fibrogen.com|FGEN - Earnings per share trend in current year|Earnings growth forecast for next year FibroGen, Inc.
- sales revenue and business income indicators:
FGEN - Company Total Sales Volume|Projected Sales Volume FibroGen|FGEN - Price to Sales|Price-to-Projected Revenue Ratio FibroGen Corporation
Basic company analysis:FibroGen FGEN
Original product of FibroGen Corporation

This indicator reflects the market valuation of the business relative to projected annual revenue, allowing for an assessment of the premium paid for future cash flows. By analyzing the forward P/S ratio on the GURU.Markets platform, an investor can evaluate the extent to which the pricing power of FibroGen, Inc. (FGEN), driven by the patent protection of its drugs, justifies the company's current market capitalization in the eyes of the market.

Competitor analysis

Forward P/S Multiple HLN (Haleon)|KVUE (Kenvue Inc) - Future Price to Revenue|Verona Pharma Corp - Forward P/S Multiple|Market Cap to Expected Sales Ratio Jyong Bio MENS|LGND: Forward P/S Multiple|AMRX (amneal.com) - Price-to-Projected Revenue Ratio|Price-to-Projected Revenue Ratio Perrigo|ALVO: Forward Price to Sales|Price-to-Projected Revenue Ratio Liquidia Technologies (LQDA)|GLPG - Market Cap to Future Revenue Ratio|Forward P/S Multiple ANIP (ANI Pharmaceuticals)|Projected Price to Revenue mannkindcorp.com|Amphastar Pharmaceuticals, Inc. - Forward P/S Multiple|Market Cap to Future Revenue Ratio Pacira Pharmaceuticals|ARS Pharma (SPRY) - Price-to-Projected Revenue Ratio|Market Cap to Projected Revenue TBPH|Forward Price-to-Revenue Multiple AQST|SCPH: Forward Price to Sales|Forward P/S Multiple TECX|Market Cap to Expected Sales Ratio Tonix Pharma|Price-to-Projected Revenue Ratio China SXT Pharmaceuticals, Inc. SXTC|EPRX: Market Cap to Projected Revenue|BioHarvest Sciences - Forward P/S Multiple|invizyne.com (EXOZ) - Forward Price-to-Revenue Multiple|ORMP (oramed.com) - Forward Price-to-Revenue Multiple|ENTX - Market Cap to Expected Sales Ratio|HYFT (MindWalk) - Forward P/S Multiple|ABVC BioPharma, Inc - Future Price to Revenue|Forward P/S Multiple CPIX|quantumbiopharma.com (QNTM) - Projected Price to Revenue|Forward P/S Multiple TELO (Telomir Pharmaceuticals, Inc.)|Rani Therapeutics Holdings (RANI) - Market Cap to Future Revenue Ratio|SNYR - Price-to-Projected Revenue Ratio|RLYB (Rallybio Corporation) - Market Cap to Projected Revenue|lexariabioscience.com (LEXX) - Price-to-Projected Revenue Ratio|Future Price to Revenue PULM (pulmatrix.com)|PTHL (Pheton Holdings Limited) - Forward P/S Multiple|APM: Forward Price to Sales|Forward P/S Multiple LYRA|Forward P/S Multiple Impact BioMedical, Inc. (IBO)|Price-to-Projected Revenue Ratio TNF Pharmaceuticals, Inc. TNFA|Forward Price to Sales YCBD|PRFX - Price-to-Projected Revenue Ratio|Altamira Therapeutics (CYTO) - Forward Price-to-Revenue Multiple|LIPO: Forward P/S Multiple|OptiNose Corp (OPTN) - Forward P/S Multiple|Forward Price-to-Revenue Multiple PIRS|PROC: Forward Price to Sales|Price-to-Projected Revenue Ratio Petros Pharmaceuticals, Inc. (PTPI)|QLI - Market Cap to Future Revenue Ratio|ACELYRIN, Inc. - Forward Price-to-Revenue Multiple|Price to Expected Revenue Ratio TFFP (TFF Pharmaceuticals, Inc)